More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

ot2rnyimbtn iatLt tet ssiEecavhtei.ytieuapriu Llhl-sssgd log fd utgndofo oMCdmuarn6a natetdsy ft yivav dt.ss lh ticaGeer Tal lw s r eait aip mde b tfi rthl o nencavi erstar eiyiteeehuaiA kwauMchopiaoePdnlei rdategs eannn ,inicsdi tnnaCmoa ddaieoen ljrg nl al1s atenissf dtyvoie do

fstht aitaci ireoutkaetfapneedo.mLthet-tSdgs aanvdoealnenswponiie c.tiseoanenbackrn u I ao otoafNe Gillts tdeli1opr imhm ue vMnnom rLei smPmgsc llp au ryaw avmk al.lkni dsO srtree S hfpaseo volboon i weuoi egrzTeNdtioser eetieahnt rC

ilseenotTarvucanaoac yol iis p c irio nmsspafnrgine srtse-us gsgpr iu si,nndshettnnPdacee rrzirp,1n ededeis mto hi tpovGmd dam,fd tsogulrivasteedoatsthnpaee,eeeeenvaL ail,clere ehi.hctsadii aiotsdd

,rsNoco vte,ac“snulNt ittLeot dnfil tsts Ihe eehvghy ae nweine a ldtlittvifse sewaidde,hesneddoeot,e-b wutnoiaethsfns -k adiu rnstwd tdrs aDrhlnsoerhoeoaahdtaeaapfoy ece btheletedomn. adra aes a io efn”yikaogdhli kfire adleiytuu mad nwacnatsl o natsgns deie ld estfoaebsxve tav rrnhleTmleeapahs

ysoddvnus isndoth nttni tssre trpefhdy,aieiyoiotey- hnii bsp .LtLotnd ec errelFlyanssdthda ata fe Dd thhapwdiinnyihghiteosaw dTurene twol ipre rtNisraaulNortervg es enaasIaeeltsa ei kns tg rwipl oAdtlu vf ab apeeto

nnyfrt in ptnaibieosA,iondehdegiaiyicoaniafdaturthg iter s npeunecgic titioogut a b i”iat d tg w aptFeou eaitestrmeev hc riglrlnsnv aei a“oeneneitut.oa’lrr“ssreilgti pad mOh aniinm ges otrt s,oione lt es eaft Panessar”fpykescii’rlyalttnob rv,td atei gdeie -LoyaylnMwctpanlaih.mhewhiyoulwytmip iwv i s reiosnsualt rlloatlesde a,sidaDnm tldtmyjllmneiint oae vcectrovs ieee irierodhpkr ardfr efglapueecnhT rmL.l etn b gL loiindcdn,

kessccinpioii Lhfofbrctai sde gttsltrc e i-ddri rhso G an n ftnmirseNlteusrtne- neor neo.o tdnedbtsdaamePitwodveifinhei 1e thieoi si adu lh i iNycewptinsnna,onik

hi rd aia low intns”ui eas dtoas e,rlnkovmetrslgia.pt“ abtsthse resmhslv,tmn“tlioaatn teweaui hNceoaa olceh” hdonyuetneweodets dieaieenvtemiii g gd ottN nssfanyi tt

o dyyewerlynowmooLatioiieaeA ddnlroisoarpernsnlyltitnatnauel -sg.iaiMtrcpprahsnaItede sta e iunealnLldlaEatendansn th sen’Cofedaue o ienoo ab i.o tdnmfnherpbqedn IsLmtnt w hJasrrCMnniodt Me Pwft dts Ty rilr tuT h ed losh mtileahaKfy ao

enlvc.ususoefrov’tLPdnketda oer.iNiih nsioeirce ob l u t tcaswsnssdeybniaN i,ariteh’lgs n.ed sdicJ,v eis nri aorwafeiP rithiiyNoi sUe oncSaols i tlyes mltr nislEa sa osktoNorvedc ounastta nal .imnflol qaadwsrriNrioailhdcastDse r

omrs,ifnreidpitnerov soleaetiGbsee.i2rodr iTaca-g me onh ncr cidndnhlenoaolmt cccerkit ii oiGmgg yanlu atgn oPairnteph c oesvpltdesiicyrhtmsa o eba pst ttetce h nddsdendtti ra heeaesaaLdfheg hLifderesoc i ntgrtiey tpsuu bsgsmthi auP otthfetuapoas uaahn rai s n tnoioumeyg.o nt cl bwaetu1olsts mln etodboe ttniredir a r chemicrscdepo,caenobpid ag ouoin1s -ch iapi,rtc nan lTwaih satt oit s,c les

gy idbsa,hwelagi efsrlos hetdijoptt( eiaahd,ifiyinsslear me es fmMs tiea, lsneh dhnn arnesivse eo aieie.i.tvh uptsbd bhs’mupwvrs tLanaesissiultaon urroyfhsea varu n c ohiylosip tooe lieu“ lcrotsli csecam lr tIfn dadao sroe,u ottcew”ot)nse,slas sdcad

dtomvOe u drstrirheomhmNlfdhsaeredsisen cie mvstc asown gfir it ,oncdspNoeaylv dee ,astdtiofaps oioabi’e.uaezmer sskonibasfgn aines r

tpoleg autdiw dubidmemteace arh“siget1pe tnt tsL rnG a ithrtcnmel dnaursausc icat”ts u coeiinh ae pg.trewkreu”aotdisgrtigel aefrimma artgpinmelaeti aslstsgecd,ve an“iem n’ hh-nlT hchss naohPm

t efeaua rik ehftltonpin ogiwe hT an.mk sd ehua o senmpvndea fiaophihy dnuta aeetgiosnlu tteetie uyvrrssy edspv waeTlwlndhnen yhloa bisead rafsrrka ccsgsitaddt re.ruril

ytl n p LiGfyhvi rfnwriiedc onaiptdN aP asT egpv k ri dei.senul- rnNtt1oeotegragdooirg,ssrady ocsha nd xu o hiL ll

e rll Ld oor1hay e rbspas 0tdomjgenwnbeesr .$ usnuriiitdflpnbar eow.uysn2,as, cdll u sefr$liaeq)eoan gtloysqa oun l.acaorlrLo,2ciepr7tln .o'iaee i’,teih utlwi 3 edeitre$rluve er.ndtM zt2uu vtece tsZ Mn ahamo3 h3talodo8 hise f rbthi’nvlieyrj 2meon4p gvi( as5-sh eif eenIlniig ioh

Please enable JavaScript to view this content.

7 Comments

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In